Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target
ADial Pharmaceuticals Cut to Hold From Buy by Maxim Group
Adial Pharmaceuticals Analyst Ratings
Maxim Group Adjusts Adial Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating
Brookline Capital Markets Keeps Their Buy Rating on Adial Pharmaceuticals (ADIL)
Adial Pharmaceuticals (ADIL) Receives a Buy from Maxim Group
No Data